Updated results from KEYNOTE-426 for metastatic kidney cancer
Published: 12 Jun 2020
Views: 298
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
Dr Elizabeth Plimack talks to ecancer in an online interview for the ASCO virtual meeting 2020 about the KEYNOTE-426 study.
She outlines the trial design and explains the ongoing development of the study.
Dr Plimack discusses the updated results and maintained benefit of this combination.
Related Videos
ESMO 2020 melanoma roundup
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
28 Sep 2020
ESMO 2020 renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
25 Sep 2020
PARP inhibitors and their evolving role for the treatment of prostate cancer
Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi
24 Sep 2020
AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
22 Sep 2020
OncoAlert and ecancer weekly roundup for September 6-13, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
14 Sep 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
30 Jun 2020
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
Latest developments in metastatic prostate cancer from ESMO 2019
Prof Nick James and Prof Nicholas Mottet
30 Sep 2019
